QJM Advance Access published online on January 17, 2005
QJM, doi:10.1093/qjmed/hci015
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Rheumatology, Ipswich Hospital, Ipswich, UK
* To whom correspondence should be addressed. Background: Wegener's granulomatosis (WG), Churg Strauss syndrome (CSS) and microscopic polyangiitis (MPA) are primary systemic vasculitides (PSV), the clinical features of which have been described from tertiary centres. Aim: To provide the first clinical description of MPA from a general hospital and compare clinical features with WG and CSS. Design: Retrospective analysis of patient records. Methods: Records of 99 PSV patients attending a single hospital, from 1988 to 2000, were reviewed for: clinical features, date/age at diagnosis, sex, duration of illness, anti-neutrophil cytoplasmic antibodies (ANCA), treatment, comorbidity and deaths. Cases were classified using ACR, CHCC and Lanham criteria/definitions. Birmingham vasculitis activity scores (BVAS) and damage index (VDI) were calculated. Survival was assessed using Cox proportional hazards model and standardized mortality ratios (SMRs). Results: Compared to previous reports there was more ENT (29%) and respiratory (29%) but less renal (92%) involvement in MPA, and less ENT involvement in WG (81%). CSS showed high neurological (72%), cardiovascular (28%) and gastrointestinal (17%) involvement and the highest median (range) VDI (p = 0.01 vs. WG; p = 0.001 vs. MPA). BVAS1 was significantly lower in MPA than in WG [median (range) 15 (4-29) vs. 21 (6-39), (p = 0.001)] but not in CSS [20 (7-28), p = 0.08]. SMR (95%CI) for PSV was 4.8 (3.0-6.6); 5-year survival was 45.1% for MPA, 75.9% for WG and 68.1% for CSS. Age was a significant risk, but only to the same extent as in the reference population. When age was adjusted for, no other significant factor was found. Discussion: The clinical characteristics seen here are similar to those in previous series. There are difficulties in using the MPA CHCC definitions in classification. There is a high proportion of neurological involvement in CSS, causing permanent damage. MPA may have a poorer prognosis than WG or CSS.
Received February 2, 2004
Revised August 25, 2004
Original Papers
Primary systemic vasculitis: clinical features and mortality
2 School of Medicine, University of East Anglia, Norwich, UK
3 Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK
S.E. Lane, E-mail: suzanne.lane{at}ipswichhospital.nhs.uk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O Flossmann, P Bacon, K de Groot, D Jayne, N Rasmussen, P Seo, K Westman, and R Luqmani Development of comprehensive disease assessment in systemic vasculitis Postgrad. Med. J., March 1, 2008; 84(989): 143 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hellmich, O. Flossmann, W. L Gross, P. Bacon, J. Willem Cohen-Tervaert, L. Guillevin, D. Jayne, A. Mahr, P. A Merkel, H. Raspe, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis Ann Rheum Dis, May 1, 2007; 66(5): 605 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Flossmann, P. Bacon, K. de Groot, D. Jayne, N. Rasmussen, P. Seo, K. Westman, and R. Luqmani Development of comprehensive disease assessment in systemic vasculitis Ann Rheum Dis, March 1, 2007; 66(3): 283 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Morgan, L. Harper, J. Williams, and C. Savage Anti-Neutrophil Cytoplasm-Associated Glomerulonephritis J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1224 - 1234. [Abstract] [Full Text] [PDF]
|
|